**ANNOUNCEMENT NO. 328**

11 November 2026

**Major shareholder announcement - BlackRock, Inc.**

Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec A/S that, on 6 November 2026, BlackRock, Inc. increased its voting rights attached to shares in ChemoMetec A/S to 15.02%, thereby exceeding the 15% threshold pursuant to section 38 of the Danish Capital Markets Act.

BlackRock, Inc.'s position at that time was as follows:

- Voting rights attached to shares: 15.02%
- Voting rights through financial instruments: 0.22%
- The total of both: 15.24%

**Additional Information**

Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80

Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80

**About ChemoMetec A/S**

*ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies.*

*ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.*